BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRx (CVRX)CVRxEarnings

MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and

Related news

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

ACHCAcadia Healthcare2026-07-28 20:05 EST

Acadia Healthcare Announces Second Quarter 2026 Results and Updates Full Year 2026 Financial and Cash Flow Guidance

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

CVRXCVRx2026-06-09 11:30 EST

CVRx Announces Chief Financial Officer Transition

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Stock data

Close
5.94 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States